Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment

Advanced NanoTherapies, Inc. (ANT) has successfully closed an oversubscribed Series B financing round, raising over $31 million. The financing was co-led by an undisclosed strategic investor and S3 Ventures, with participation from the T45 Fund and other new and existing investors. This funding will primarily support the approval process for the U.S. Investigational Device Exemption (IDE) and facilitate clinical advancements for ANT's innovative dual-drug nanoparticle-coated balloon platform aimed at treating vascular diseases.

ANT, based in Santa Clara, California, is a clinical-stage medtech company focused on enhancing treatment outcomes for patients with coronary and peripheral artery disease. The company's flagship product, SirPlux Duo, represents a significant advancement in drug-coated balloon (DCB) therapy, utilizing a proprietary nanoparticle delivery system to enhance drug uptake within the vessel wall. By combining two established antiproliferation agents, sirolimus and paclitaxel, the device aims to deliver superior therapeutic effects while promoting a more predictable and sustained vascular response compared to traditional single-drug DCBs.

The strategic rationale behind this financing is underscored by the growing clinical challenges associated with restenosis following percutaneous coronary interventions (PCI). Current first-generation DCBs, while gaining traction in the U.S. market, often fall short due to the limitations of passive crystalline drug delivery. ANT's dual-drug approach seeks to address these shortcomings by enabling simultaneous drug delivery at the treatment site, which could lead to improved patient outcomes and reduced rates of treatment failure. The technology is exclusively licensed from the Cleveland Clinic, further bolstering its credibility in the medical community.

The funding will also facilitate the scaling of manufacturing processes to meet FDA IDE requirements for both coronary and peripheral applications. ANT plans to submit IDE applications for two coronary indications—specifically targeting in-stent restenosis and small-vessel de novo lesions—while also pursuing a pivotal clinical trial agreement with the FDA. Additionally, the company is looking to establish clinical sites outside the U.S. as part of its early pivotal enrollment strategy.

This financing round not only validates ANT's innovative platform but also reflects broader trends in the healthcare technology sector, where there is a growing emphasis on developing differentiated therapies that address unmet clinical needs. As the market for vascular interventions continues to evolve, ANT's advancements may pave the way for improved treatment options, potentially reshaping the landscape of DCB therapy. The successful execution of its clinical and regulatory strategies will be crucial for ANT as it seeks to bring its groundbreaking technology to market, ultimately aiming to provide better solutions for patients suffering from vascular diseases.